Maastricht, Netherlands
Maastricht, Netherlands

Time filter

Source Type

IRVINE, CA, et HERSTAL, BELGIQUE - 07:00 CEST - Le 5 mai 2017 - MDxHealth SA (Euronext: MDXH.BR), a annoncé aujourd'hui avoir signé un accord avec la Faculté de santé, de médecine et de sciences de la vie / Ecole d'oncologie et de biologie du développement (GROW) de l'Université de Maastricht pour étendre son actuelle collaboration de recherche et ainsi développer commercialement une nouvelle génération de tests (épi)génétiques de diagnostic oncologique. Selon les termes de l'accord pluriannuel de R & D, la collaboration se concentrera sur le développement de tests (épi)génétiques qui devraient permettre un diagnostic, une identification du stade et un traitement des patients cancéreux de meilleure qualité. Pour ces tests de nouvelle génération, l'accent sera mis sur l'échantillonnage et sur le résultat des plates-formes basées. Cette technologie pourrait également être appliquée aux tests actuels et futurs de biopsie liquide de MDxHealth, y compris au test SelectMDx (TM) for Prostate Cancer. "GROW à l'Université de Maastricht sont de véritables visionnaires et nous avons la chance d'avoir une relation de collaboration aussi longue", a déclaré le Dr Jan Groen, CEO de MDxHealth. "Le développement d'une nouvelle génération de tests de diagnostic oncologique de biopsie liquide va changer le jeu et aider les médecins à gérer leurs patients de façon plus rapide et plus efficace". GROW est l'Ecole d'oncologie et de biologie du développement du Centre médical de l'Université de Maastricht (MUMC +) aux Pays-Bas et est accréditée par l'Académie Royale des Arts et des Sciences (KNAW). GROW se concentre sur la recherche et l'enseignement des concepts (épi)génétiques et cellulaires, ainsi que sur les (micro) facteurs environnementaux sous-jacents au développement normal et anormal. En mettant l'accent sur la recherche translationnelle, les chercheurs et les cliniciens de GROW visent à traduire ces connaissances de base en approches novatrices pour individualiser la prévention, le diagnostic du patient et le traitement du cancer. Vous trouverez plus d'informations sur GROW à l'adresse: http://www.grow-um.nl. MDxHealth est une société multinationale, active dans le domaine des soins de santé, qui fournit des informations de diagnostic moléculaire pratiques afin de personnaliser le diagnostic et le traitement du cancer. Les tests de la société sont basés sur la technologie génétique et épigénétique (méthylation) et sur d'autres technologies moléculaires brevetées.  Ses tests ont pour but d'aider les médecins dans leur diagnostic des cancers urologiques, dans leur pronostic de risque de résurgence et dans la prédiction de la réponse du patient à une thérapie spécifique.   Le siège social de la Société est basé à Herstal en Belgique et son laboratoire à Nimègue aux Pays-Bas.  Son siège social et son laboratoire américains sont basés à Irvine en Californie. Pour plus d'informations, visitez le site web: www.mdxhealth.com ou suivez-nous sur Twitter : twitter.com/mdxhealth. Le Campus de soins Brightlands de Maastricht réunit des scientifiques brillants et des entrepreneurs opportunistes afin de créer l'un des écosystèmes les plus importants d'Europe relatif aux sciences de la vie et à la santé. Le Campus abrite des institutions scientifiques et cliniques comme le Centre médical de l'Université de Maastricht, la Faculté de santé, de médecine et de sciences de la vie de l'Université de Maastricht et la Clinique Maastro de radiothérapie. En outre, il compte plus de 70 start-up et PME, ainsi que des multinationales de renom comme Bayer Healthcare, Boston Scientific et Medtronic. Ses centres d'intérêt comprennent, entre autres, la médecine régénératrice, la médecine de précision et les diagnostics innovants. Pour plus d'informations, visitez https://www.brightlands.com. Informations importantes concernant les informations prévisionnelles Ce communiqué de presse contient des informations prévisionnelles et des estimations relatives aux performances futures prévues de MDxHealth et du marché sur lequel la société est active. Lesdites déclarations et estimations se basent sur différentes suppositions et appréciations de risques connus et inconnus, d'incertitudes et d'autres facteurs, qui semblaient raisonnables lorsqu'elles ont été réalisées, mais qui pourront s'avérer correctes ou non. Les événements réels sont difficiles à prévoir et peuvent dépendre de facteurs au-delà du contrôle de la société, et peuvent s'avérer être substantiellement différents. MDxHealth réfute expressément toute obligation de mise à jour des informations prévisionnelles de ce rapport intermédiaire et ce, dans le but de refléter tout changement par rapport à ses attentes, tout changement des événements, des conditions ou des circonstances sur lesquels un tel rapport est basé à moins que ce soit requis par la loi ou un règlement. Ce communiqué de presse ne constitue pas une offre ou une invitation de vente ou d'achat de titres ou d'actifs de MDxHealth dans quelque juridiction que ce soit. Aucun titre de MDxHealth ne peut être offert ou vendu aux États-Unis sans inscription préalable et ce en vertu du US Securities Act de 1933, tel que modifié, ou dans le respect d'une dispense, et en conformité avec toutes les lois applicables aux valeurs mobilières aux Etats-Unis.


IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, May 5, 2017 - MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed an agreement with the Faculty of Health, Medicine and Life Sciences / School for Oncology and Developmental Biology (GROW) at Maastricht University to expand its existing research collaboration to develop commercial next generation (epi)genetic cancer diagnostics. Under the terms of the multi-year R&D agreement, the collaboration will focus on developing (epi)genetic-based assays to provide better insight in the diagnosis, staging and treatment of cancer patients. For these next generation assays, the focus will be on sample in and result out based platforms. This technology would also be applied to MDxHealth's current and upcoming liquid biopsy tests including SelectMDx(TM) for Prostate Cancer. "GROW at Maastricht University are true visionaries and we are fortunate to have such a long-standing and collaborative relationship," said Dr. Jan Groen, CEO of MDxHealth. "The development of next generation liquid biopsy diagnostics for oncology will be game-changing and help physicians manage their patients faster and more effectively." "As a thought-leader in epigenetics, MDxHealth is the ideal partner to collaborate on next generation (epi)genetic diagnostics," said Prof. Dr. Manon van Engeland, Professor of Pathobiology of Cancer and Scientific Vice-Director of GROW. "MDxHealth's expanding portfolio of liquid biopsy tests are ideal to run on the assays we're in the process of developing." "We are delighted that MDxHealth is joining our science business community at the Brightlands Maastricht Health Campus," said Jan Cobbenhagen, CEO of the Brightlands Maastricht Health Campus. "MDxHealth fits perfectly in our thriving ecosystem of startups, SMEs, multinationals and renowned knowledge institutions.'' GROW is the School for Oncology and Developmental Biology at the Maastricht University Medical Centre (MUMC+), The Netherlands, and accredited by the Royal Academy of Arts and Sciences (KNAW). GROW focuses on research and teaching of (epi)genetic and cellular concepts, as well as (micro)environmental factors underlying normal and abnormal development. With a strong emphasis on translational research, scientists and clinicians within GROW aim at implementing basic knowledge into innovative approaches for individualizing prevention, patient diagnostics and treatment of cancer. More information about GROW is available at http://www.grow-um.nl. MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth. Brightlands Maastricht Health Campus brings together brilliant scientists and opportunity-driven entrepreneurs to create one of Europe's most prominent ecosystems for Life Science and Health. The campus is home to scientific and clinical institutions like the Maastricht University Medical Center, the Faculty of Health, Medicine and Life Sciences of Maastricht University, and the Maastro Clinic for Radiation Therapy. Furthermore, it harbors over 70 start-up companies and SMEs, as well as renowned multinationals like Bayer Healthcare, Boston Scientific, and Medtronic. Focus areas include, amongst others, Regenerative Medicine, Precision Medicine, and Innovative Diagnostics. For more information, visit https://www.brightlands.com. This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws. NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.


Corcoran M.S.,MUMC | van Well G.T.J.,MUMC | van Well G.T.J.,Maastricht University | van Loo I.H.M.,School for Public Health and Primary Care
European Journal of Clinical Microbiology and Infectious Diseases | Year: 2014

Molecular methods such as real-time polymerase chain reaction (PCR) are rapidly replacing traditional tests to detect fecal viral pathogens in childhood diarrhea. This technique has now increased the analytical sensitivity so drastically that positive results are found in asymptomatic children, leading to complex interpretation of real-time PCR results and difficult distinction between asymptomatic shedding and etiological cause of disease. We performed a review of the literature including pediatric studies using real-time PCR and a minimal inclusion period of one year to exclude bias by seasonality. We searched for studies on rotavirus, norovirus, adenovirus, astrovirus, and sapovirus, known to be the most common viruses to cause gastroenteritis in the pediatric population. For these viruses, we summarized the detection rates in hospitalized and community-based children with clinical symptoms of gastroenteritis, as well as subjects with asymptomatic viral shedding. Moreover, insight is given into the different viral sero- and genotypes causing pediatric gastroenteritis. We also discuss the scoring systems for severity of disease and their clinical value. A few published proposals have been made to improve the clinical interpretation of real-time PCR results, which we recapitulate and discuss in this review. We propose using the semi-quantitative measure of real-time PCR, as a surrogate for viral load, in relation to the severity score to distinguish asymptomatic viral shedding from clinically relevant disease. Overall, this review provides a better understanding of the scope of childhood gastroenteritis, discusses a method to enhance the interpretation of real-time PCR results, and proposes conditions for future research to enhance clinical implementation. © 2014, Springer-Verlag Berlin Heidelberg.


Bauwens M.,MUMC | Bauwens M.,Maastricht University | Wierts R.,MUMC | Van Royen B.,MUMC | And 5 more authors.
European Journal of Nuclear Medicine and Molecular Imaging | Year: 2014

Purpose: Brown adipose tissue (BAT) has transformed from an interfering tissue in oncological 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to an independent imaging research field. This review takes the perspective from the imaging methodology on which human BAT research has come to rely on heavily. Methods: This review analyses relevant PubMed-indexed publications that discuss molecular imaging methods of BAT. In addition, reported links between BAT and human diseases such as obesity are discussed, and the possibilities for imaging in these fields are highlighted. Radiopharmaceuticals aiming at several different biological mechanisms of BAT are discussed and evaluated. Results: Prospective, dedicated studies allow visualization of BAT function in a high percentage of human subjects. BAT dysfunction has been implicated in obesity, linked with diabetes and associated with cachexia and atherosclerosis. Presently, 18F-FDG PET/CT is the most useful tool for evaluating therapies aiming at BAT activity. In addition to 18F-FDG, other radiopharmaceuticals such as 99mTc- sestamibi, 123I-metaiodobenzylguanidine (MIBG), 18F- fluorodopa and 18F-14(R,S)-[18F]fluoro-6-thia- heptadecanoic acid (FTHA) may have a potential for visualizing other aspects of BAT activity. MRI methods are under continuous development and provide the prospect of functional imaging without ionizing radiation. Conclusion: Molecular imaging of BAT can be used to quantitatively assess different aspects of BAT metabolic activity. © 2014 Springer-Verlag.


Nijhuis R.,Rijnstate | Samuelsen T.,University of Tromsø | Savelkoul P.,MUMC | van Zwet A.,Rijnstate
Diagnostic Microbiology and Infectious Disease | Year: 2013

To prevent the spread of carbapenemase-producing bacteria, a fast and accurate detection of patients carrying these bacteria is extremely important. The Check-Direct CPE assay (Check-Points, Wageningen, The Netherlands) is a new multiplex real-time PCR assay, which has been developed to detect and differentiate between the most prevalent carbapenemase genes encountered in Enterobacteriaceae (blaKPC, blaOXA-48, blaVIM, and blaNDM) directly from rectal swabs. Evaluation of this assay using 83 non-duplicate isolates demonstrated 100% sensitivity and specificity and the correct identification of the carbapenemase gene(s) present in all carbapenemase-producing isolates. Moreover, the limit of detection (LoD) of the real-time PCR assay in spiked rectal swabs was determined and showed comparable LoDs with the ChromID CARBA agar. With an excellent performance on clinical isolates and spiked rectal swabs, this assay appeared to be an accurate and rapid method to detect blaKPC, blaOXA-48, blaVIM, and blaNDM genes directly from a rectal screening swab. © 2013 Elsevier Inc.


Vaes A.W.,Program Development Center | Cheung A.,Catharina Hospital | Atakhorrami M.,Philips | Groenen M.T.J.,Program Development Center | And 4 more authors.
Annals of Medicine | Year: 2013

Aim. This review evaluated the effects of activity monitor-based counseling on physical activity (PA) and generic and disease-specific health-related outcomes in adults with diabetes mellitus type II (DMII), chronic obstructive pulmonary disease (COPD), or chronic heart failure (CHF). Methods. Four electronic databases were searched for randomized controlled trials using activity monitor-based counseling versus control intervention or usual care in adults with DMII, COPD, or CHF. Pooled effect sizes were calculated using a random effects model. Results. Twenty-four articles were included: 21 DMII studies and 3 COPD studies. No CHF studies were identified. Pooled analysis showed that activity monitor-based counseling resulted in a significantly greater improvement in PA compared to control intervention or usual care in DMII. Furthermore, these interventions had a beneficial effect on hemoglobin A1c (HbA1c), systolic blood pressure, and body mass index (BMI) (P < 0.05), whereas no differences were found on diastolic blood pressure, and health-related quality of life. Meta-analysis of COPD studies was not possible due to lack of available data. Conclusion. Activity monitor-based counseling had a beneficial effect on PA, HbA1c, systolic blood pressure, and BMI in patients with DMII. Data in patients with COPD and CHF are limited or non-existing, respectively. © 2013 Informa UK, Ltd.


Hyperinflation is an important element in chronic obstructive pulmonary disease (COPD), contributing significantly to dyspnoea and exercise intolerance. Bronchodilators have some, albeit slight, effect on hyperinflation. Lung volume reduction surgery has been advocated in a highly select group of patients with heterogeneous, predominantly upper lobe, emphysema but morbidity and mortality associated with this intervention have hampered its widespread use in respiratory medicine. Bronchoscopic lung volume reduction has recently been introduced. Several studies have shown promising results, again in a highly select group of patients, with clinically relevant effects on symptoms, lung function and quality of life. However, for most COPD patients, prevention and slowing down of disease progression are much more important. Smoking cessation is the single most important intervention to achieve these goals. Furthermore, effective new anti-inflammatory drugs are needed since inhaled steroids, although widely used in COPD, are largely ineffective.


Van Gorkom G.N.Y.,MUMC
Nederlands Tijdschrift voor Geneeskunde | Year: 2013

A 64-year-old man presented with a slowly progressive left-sided orbital swelling that had been present for years. MRI of the orbits showed hypertrophic ocular muscles. Histopathological examination of a biopsy confirmed the diagnosis of small B-cell non-Hodgkin lymphoma.


Pannier F.,MUMC | Rabe E.,University of Bonn | Rits J.,Riga Vein Center | Kadiss A.,Riga Vein Center | Maurins U.,Riga Vein Center
Phlebology | Year: 2011

Background: Endovenous laser ablation (EVLA) is an efficient method to treat insufficient great saphenous veins (GSV) with high occlusion rates. 1-5 Most studies used 810, 940 or 980 nm diode lasers and a bare fibre. 1,2,6 Moderate postoperative pain and bruising are frequent findings. 2,6 Laser systems with higher wavelengths like 1470 nm with a higher absorption in water show less pain and bruising after the procedure. 7-9 A newlydeveloped fibre (radial fibre, Biolitec) emits the laser energy radially around the tip directly into the venous wall contrary to the bare fibre. 9 The aim of this study was to demonstrate the outcome and side-effects after EVLA of GSV with a 1470 nm diode laser (Ceralas E, Biolitec) by using the radial fibre. Methods: Non-randomized, prospective study including 50 unselected limbs of 50 patients with a duplex sonographically verified incompetent GSV. EVLA was performed with a 1470 nm diode laser (Ceralas E, Biolitec) and a radial fibre. In the same session all insufficient tributaries were treated by phlebectomy. Tumescent local anaesthesia with 0.05% lidocaine was applied perivenously. Laser treatment was carried out in a continuous mode with a power of 15W. Compression stockings (30 mmHg) were applied for one month. Postinterventional checkups took place one, 10, 30 days and six months after the procedure. Results: Three patients were lost to follow-up. The average linear endovenous energy density (LEED) was 90.8 J/cm vein (SD 35.3). At the six month follow-up all treated veins remained occluded and no new reflux in the treated segments occurred. No recurrent varicose veins had occurred so far. No severe complications such as deep venous thrombosis could be detected. In four patients at 30 days and three patients at six months local paresthesia occurred in the region of EVLA. Forty-four percent of patients did not have any pain after the treatment and 50% did not take any analgesic tablets at any time after the procedure. Postoperative ecchymoses in the track of the treated GSV was rare. In 80% of the limbs, no ecchymoses was observed after the treatment. Conclusion: EVLA of GSV with a radially emitting laser fibre by using a 1470 nmdiode laser is a safe and efficient treatment option.


An increasing number of people with mild cognitive impairment (MCI) visits a memory clinic to find out whether their symptoms indicate Alzheimer's disease (AD). Markers in cerebrospinal fluid are increasingly used for the diagnosis of Alzheimer's disease. In the short term, CSF biomarkers are more accurate in ruling out progression to AD-type dementia than demonstrating progression. The predictive value of the CSF biomarkers increases with longer-duration follow-up and declines with age. The added value of CSF biomarkers is not yet clear in MCI patients in whom extensive clinical, neuropsychological examination or imaging have already been performed.

Loading MUMC collaborators
Loading MUMC collaborators